893 related articles for article (PubMed ID: 16580075)
1. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
[TBL] [Abstract][Full Text] [Related]
2. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
[TBL] [Abstract][Full Text] [Related]
3. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488
[TBL] [Abstract][Full Text] [Related]
5. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306
[TBL] [Abstract][Full Text] [Related]
6. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
[TBL] [Abstract][Full Text] [Related]
8. Cytokine responses to EHV-1 infection in immune and non-immune ponies.
Coombs DK; Patton T; Kohler AK; Soboll G; Breathnach C; Townsend HG; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):109-16. PubMed ID: 16473413
[TBL] [Abstract][Full Text] [Related]
9. The equine immune response to equine herpesvirus-1: the virus and its vaccines.
Kydd JH; Townsend HG; Hannant D
Vet Immunol Immunopathol; 2006 May; 111(1-2):15-30. PubMed ID: 16476492
[TBL] [Abstract][Full Text] [Related]
10. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse.
Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414
[TBL] [Abstract][Full Text] [Related]
11. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges.
Patel JR; Földi J; Bateman H; Williams J; Didlick S; Stark R
Vet Microbiol; 2003 Mar; 92(1-2):1-17. PubMed ID: 12488066
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).
Goodman LB; Wagner B; Flaminio MJ; Sussman KH; Metzger SM; Holland R; Osterrieder N
Vaccine; 2006 Apr; 24(17):3636-45. PubMed ID: 16513225
[TBL] [Abstract][Full Text] [Related]
14. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
[TBL] [Abstract][Full Text] [Related]
15. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus).
Fitzpatrick DR; Studdert MJ
Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822
[TBL] [Abstract][Full Text] [Related]
16. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N
Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Breathnach CC; Rudersdorf R; Lunn DP
Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222
[TBL] [Abstract][Full Text] [Related]
18. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.
Schnabel CL; Babasyan S; Rollins A; Freer H; Wimer CL; Perkins GA; Raza F; Osterrieder N; Wagner B
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462575
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
Heldens JG; Pouwels HG; van Loon AA
Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389
[TBL] [Abstract][Full Text] [Related]
20. Intranasal IgG4/7 antibody responses protect horses against equid herpesvirus-1 (EHV-1) infection including nasal virus shedding and cell-associated viremia.
Perkins G; Babasyan S; Stout AE; Freer H; Rollins A; Wimer CL; Wagner B
Virology; 2019 May; 531():219-232. PubMed ID: 30928700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
